Wardex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 07-07-2024
- Paid Up Capital ₹ 4.20 M
as on 07-07-2024
- Company Age 78 Year, 4 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.94 Cr
as on 07-07-2024
- Revenue -3.55%
(FY 2023)
- Profit -10.04%
(FY 2023)
- Ebitda 16.28%
(FY 2023)
- Net Worth 9.76%
(FY 2023)
- Total Assets 11.82%
(FY 2023)
About Wardex Pharmaceuticals
The Corporate was formerly known as Ward Blenkinsop & Co. (India) Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.20 M.
The company currently has active open charges totaling ₹1.94 Cr.
Venkatraman Subramaniam, Syed Rizvi, Vitalapuram Subramanian, and Three other members serve as directors at the Company.
- CIN/LLPIN
U51397TN1946PTC005759
- Company No.
005759
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Dec 1946
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Madras-29, Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Wardex Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Alexandre Postel  | Managing Director | 24-May-2011 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Venkatraman Subramaniam | Director | 27-Jan-2018 | Current |
| Syed Rizvi | Director | 26-Feb-2021 | Current |
| Vitalapuram Subramanian | Director | 01-Feb-1999 | Current |
| Jagdish Mehta | Director | 19-Mar-2014 | Current |
| Pascal Postel | Director | 31-Dec-2020 | Current |
Financial Performance of Wardex Pharmaceuticals.
Wardex Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 3.55% decrease. The company also saw a substantial fall in profitability, with a 10.04% decrease in profit. The company's net worth moved up by a moderate rise of 9.76%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Wardex Pharmaceuticals?
In 2023, Wardex Pharmaceuticals had a public holding of 100.00%. The company had 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Franco-Indian Pharmaceuticals Private LimitedActive 65 years 7 monthsJagdish Mehta, Pascal Postel and 1 more are mutual person
Princeps Pharmaceuticals Private LimitedActive 24 years 8 monthsVitalapuram Subramanian and Pascal Postel are mutual person
- Laboratoires Griffon Private LimitedActive 77 years 6 months
Jagdish Mehta and Pascal Postel are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Bnp Paribas Creation Date: 26 Sep 2014 | ₹7.50 M | Open |
Banque Nationale De Paris Creation Date: 20 Sep 1996 | ₹6.90 M | Open |
Catholic Syrian Bank Ltd. Creation Date: 21 Dec 1982 | ₹3.00 M | Open |
How Many Employees Work at Wardex Pharmaceuticals?
Wardex Pharmaceuticals has a workforce of 109 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Wardex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Wardex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
